Hjem › Diffus sclerodermi › New York
Diffus sclerodermi kliniske forsøg i New York
9 studier for Diffus sclerodermi søger deltagere på steder i New York.
Byer i New York
Officiel studietekst (engelsk)
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- Hospital for Special Surgery, New York
RekruttererFase 2
Alder 18 til 70 · Alle køn · Opdateret 28. sep. 2026 · NCT06470048EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- NYU Langone Health, Brooklyn
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07287670A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Icahn School of Medicine at Mount Sinai, New York
RekruttererFase 1
Alder 18 til 74 · Alle køn · Opdateret 10. sep. 2026 · NCT07085104A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, New York
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT05878717Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
RekruttererFase 2/3
Alder 18 til 75 · Alle køn · Opdateret 17. aug. 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, New York
- Nkarta Investigational Site, Stony Brook
- Nkarta Investigational Site, Syracuse
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 7. aug. 2026 · NCT06733935Scleroderma Registry & Repository at the Hospital for Special Surgery
- Hospital for Special Surgery, New York
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 26. nov. 2025 · NCT01656447Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.